SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised t...
AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible vi...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight managemen...
Levi & Korsinsky Announces an Investigation on Behalf of AstraZeneca PLC (AZN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible vi...
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO A...
AstraZeneca upgrades outlook for the second time on four months
AstraZeneca PLC (LSE:AZN) raised its 2024 sales and profit outlook for the second time in under four months, following stronger-than-expected third-quarter results. The Anglo-Swedish drugs giant no...
AstraZeneca plans quick-fire $3.5bn US investment
AstraZeneca PLC (LSE:AZN) has announced a $3.5 billion investment to expand its research and manufacturing operations in the United States by 2026, with $2 billion allocated to creating more than 1...
AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines, aft...
AstraZeneca has explaining to do after £50 billion value hit
At the start of September when its share price was at an all-time high and it was comfortably the UK's largest company, AstraZeneca PLC (LSE:AZN) management might have been expecting a routine thir...
AstraZeneca hails positive phase III data for repurposed asthma treatment
AstraZeneca PLC (LSE:AZN) and Amgen Inc (NASDAQ:AMGN, ETR:AMG) have unviled positive results from their phase III WAYPOINT study, which tested the effectiveness of Tezspire (tezepelumab) in treatin...
AstraZeneca commits to cooperting with China fraud probe after billions wiped from valuation
AstraZeneca PLC (LSE:AZN) has committed to working with Chinese authorities after reports several executives were implicated in a fraud case wiped billions off its valuation on Tuesday. Financial ...
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca (AZN) shares dropped Tuesday after a report that dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case, according to a report fr...
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Astrazeneca (AZN) closed at $71.42, indicating a +0.38% shift from the previous trading day.
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
Astrazeneca (AZN) closed the most recent trading day at $75.05, moving -1.12% from the previous trading session.
Related Companies